Search :
Sign in or Register  
Welcome Sign in or Don't have an account?Register

Mouse Anti-KCNQ2 Recombinant Antibody (S26A-23) (CBMAB-K0061-LY)


See all KCNQ2 antibodies
Online Inquiry

Summary

Host Animal
Mouse
Specificity
Human, Mouse, Rat
Clone
S26A-23
Antibody Isotype
IgG1
Application
WB, IP, IF/ICC, IHC-P

Basic Information

Immunogen
Fusion protein amino acids 1-59 of human KCNQ2
Specificity
Human, Mouse, Rat
Antibody Isotype
IgG1
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Buffer
50% Glycerol
Purity
> 95% Purity determined by SDS-PAGE.
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

Target

Full Name
Potassium Voltage-Gated Channel Subfamily Q Member 2
Introduction
The M channel is a slowly activating and deactivating potassium channel that plays a critical role in the regulation of neuronal excitability. The M channel is formed by the association of the protein encoded by this gene and a related protein encoded by the KCNQ3 gene, both integral membrane proteins. M channel currents are inhibited by M1 muscarinic acetylcholine receptors and activated by retigabine, a novel anti-convulsant drug. Defects in this gene are a cause of benign familial neonatal convulsions type 1 (BFNC), also known as epilepsy, benign neonatal type 1 (EBN1). At least five transcript variants encoding five different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
Entrez Gene ID
Human3785
Mouse16536
Rat170848
UniProt ID
HumanO43526
MouseQ9Z351
RatO88943
Alternative Names
Potassium Voltage-Gated Channel Subfamily Q Member 2; Potassium Channel; Voltage Gated KQT-Like Subfamily Q; Member 2; Neuroblastoma-Specific Potassium Channel Subunit Alpha KvLQT2; Voltage-Gated Potassium Channel Subunit Kv7.2; Potassium Voltage-Gated Channel; KQT-Like Subfamily; Member 2; Potassium Voltage-Gated Channel Subfamily KQT Member 2; KQT-Like 2; KCNA11;
Function
Associates with KCNQ3 to form a potassium channel with essentially identical properties to the channel underlying the native M-current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons as well as the responsiveness to synaptic inputs. Therefore, it is important in the regulation of neuronal excitability. KCNQ2/KCNQ3 current is blocked by linopirdine and XE991, and activated by the anticonvulsant retigabine (PubMed:9836639, PubMed:11572947, PubMed:14534157, PubMed:12742592, PubMed:17872363).
As the native M-channel, the potassium channel composed of KCNQ2 and KCNQ3 is also suppressed by activation of the muscarinic acetylcholine receptor CHRM1 (PubMed:10684873).
Biological Process
Chemical synaptic transmissionManual Assertion Based On ExperimentTAS:ProtInc
Nervous system developmentManual Assertion Based On ExperimentTAS:ProtInc
Potassium ion transmembrane transportManual Assertion Based On ExperimentIDA:UniProtKB
Regulation of ion transmembrane transportIEA:UniProtKB-KW
Cellular Location
Cell membrane
Involvement in disease
Seizures, benign familial neonatal 1 (BFNS1):
A disorder characterized by clusters of seizures occurring in the first days of life. Most patients have spontaneous remission by 12 months of age and show normal psychomotor development. Some rare cases manifest an atypical severe phenotype associated with epileptic encephalopathy and psychomotor retardation. The disorder is distinguished from benign familial infantile seizures by an earlier age at onset. In some patients, neonatal convulsions are followed later in life by myokymia, a benign condition characterized by spontaneous involuntary contractions of skeletal muscles fiber groups that can be observed as vermiform movement of the overlying skin. Electromyography typically shows continuous motor unit activity with spontaneous oligo- and multiplet-discharges of high intraburst frequency (myokymic discharges). Some patients may have isolated myokymia.
Developmental and epileptic encephalopathy 7 (DEE7):
An autosomal dominant seizure disorder characterized by infantile onset of refractory seizures with resultant delayed neurologic development and persistent neurologic abnormalities.
Topology
Cytoplasmic: 1-91
Helical: 92-112
Extracellular: 113-122
Helical: 123-143
Cytoplasmic: 144-166
Helical: 167-187
Extracellular: 188-195
Helical: 196-218
Cytoplasmic: 219-231
Helical: 232-252
Extracellular: 253-264
Pore-forming: 265-285
Extracellular: 286-291
Helical: 292-312
Cytoplasmic: 313-872
PTM
KCNQ2/KCNQ3 heteromeric current can be increased by intracellular cyclic AMP, an effect that depends on phosphorylation of Ser-52 in the N-terminal region.
KCNQ2/KCNQ3 are ubiquitinated by NEDD4L. Ubiquitination leads to protein degradation (Probable). Degradation induced by NEDD4L is inhibited by USP36 (PubMed:27445338).
More Infomation

Vanoye, C. G., Desai, R. R., Ji, Z., Adusumilli, S., Jairam, N., Ghabra, N., ... & George Jr, A. L. (2022). High-throughput evaluation of epilepsy-associated KCNQ2 variants reveals functional and pharmacological heterogeneity. JCI insight, 7(5).

Miceli, F., Soldovieri, M. V., Weckhuysen, S., Cooper, E., & Taglialatela, M. (2022). KCNQ2-related disorders.

Soh, H., Springer, K., Doci, K., Balsbaugh, J. L., & Tzingounis, A. V. (2022). KCNQ2 and KCNQ5 form heteromeric channels independent of KCNQ3. Proceedings of the National Academy of Sciences, 119(13), e2117640119.

Boets, S., Johannesen, K. M., Destree, A., Manti, F., Ramantani, G., Lesca, G., ... & Weckhuysen, S. (2022). Adult phenotype of KCNQ2 encephalopathy. Journal of Medical Genetics, 59(6), 528-535.

Brun, L., Viemari, J. C., & Villard, L. (2022). Mouse models of Kcnq2 dysfunction. Epilepsia, 63(11), 2813-2826.

Li, X., Zhang, Q., Guo, P., Fu, J., Mei, L., Lv, D., ... & Guo, J. (2021). Molecular basis for ligand activation of the human KCNQ2 channel. Cell Research, 31(1), 52-61.

Kim, H. J., Yang, D., Kim, S. H., Won, D., Kim, H. D., Lee, J. S., ... & Kang, H. C. (2021). Clinical characteristics of KCNQ2 encephalopathy. Brain and Development, 43(2), 244-250.

Springer, K., Varghese, N., & Tzingounis, A. V. (2021). Flexible stoichiometry: implications for KCNQ2-and KCNQ3-associated neurodevelopmental disorders. Developmental neuroscience, 43(3-4), 191-200.

Kuersten, M., Tacke, M., Gerstl, L., Hoelz, H., Stülpnagel, C. V., & Borggraefe, I. (2020). Antiepileptic therapy approaches in KCNQ2 related epilepsy: a systematic review. European Journal of Medical Genetics, 63(1), 103628.

Malerba, F., Alberini, G., Balagura, G., Marchese, F., Amadori, E., Riva, A., ... & Striano, P. (2020). Genotype-phenotype correlations in patients with de novo KCNQ2 pathogenic variants. Neurology Genetics, 6(6).

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-KCNQ2 Recombinant Antibody (S26A-23)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Learn more

Documents

Request bulk or custom quoteOnline Inquiry
Second antibody and isotype control

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Online Inquiry